Public awareness has long focused on the risks of the transmission of viral agents through blood product transfusion. This risk, however, pales in comparison to the less publicized danger associated with the transfusion of blood products contaminated with bacteria, in particular, platelet concentrates. Up to 1,000 cases of clinical sepsis after the transfusion of platelet concentrates are repor...

In the last 10 years three technologies capable of inactivating pathogens in platelet concentrates have been authorized in Europe although only one based on the addition of amotosalen and illumination with ultraviolet A (UVA) light, has been approved by the National Agency for the Safety of Medicines and Health Products (ANSM). An intense debate exists about the implementation of pathogen inact...

It is accepted that replantation is the treatment of choice for avulsed teeth, however resorption and ankylosis are frequent complications in clinical practice. In such situation it is clinically relevant to evaluate the effectiveness of platelet concentrates in reducing these complications and improving the prognosis for the tooth. The object of this review was to analyse the available evidenc...

BACKGROUND The recent emergence of autologous blood concentrates, such as platelet-rich plasma, as a treatment option for patients with orthopaedic injuries has led to an extensive debate about their clinical benefit. We conducted a systematic review and meta-analysis to determine the efficacy of autologous blood concentrates in decreasing pain and improving healing and function in patients wit...

In a series of important studies Murphy and his colleagues demonstrated that the preparation and storage of platelet-rich plasma and platelet concentrates at 22°C rather than 4°C improved their life span in vivo (Murphy and Gardner, 1969; Murphy, Sayar, and Gardner, 1970). The potential clinical relevance of this finding has been confirmed by Handin and Valeri (1971), and it is likely that this...